Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma.
Biopharmaceutical Company Demonstrates Positive Results In Lymphoma Treatment: $2.6M FDA Grant
Biopharmaceutical Company Demonstrates…
Biopharmaceutical Company Demonstrates Positive Results In Lymphoma Treatment: $2.6M FDA Grant
Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma.